These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37797892)

  • 1. Long-acting injectable multipurpose prevention technology for prevention of HIV and unplanned pregnancy.
    Young IC; Pallerla A; Cottrell ML; Maturavongsadit P; Prasher A; Shrivastava R; De la Cruz G; Montgomery SA; Schauer A; Sykes C; Kashuba ADM; Benhabbour SR
    J Control Release; 2023 Nov; 363():606-620. PubMed ID: 37797892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection.
    Young IC; Massud I; Cottrell ML; Shrivastava R; Maturavongsadit P; Prasher A; Wong-Sam A; Dinh C; Edwards T; Mrotz V; Mitchell J; Seixas JN; Pallerla A; Thorson A; Schauer A; Sykes C; De la Cruz G; Montgomery SA; Kashuba ADM; Heneine W; Dobard CW; Kovarova M; Garcia JV; García-Lerma JG; Benhabbour SR
    Nat Commun; 2023 Feb; 14(1):708. PubMed ID: 36759645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-Ranging Plasma and Genital Tissue Pharmacokinetics and Biodegradation of Ultra-Long-Acting Cabotegravir In Situ Forming Implant.
    Young IC; Thorson AL; Shrivastava R; Sykes C; Schauer AP; Cottrell ML; Kashuba ADM; Benhabbour SR
    Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model.
    Smith JM; Moss JA; Srinivasan P; Butkyavichene I; Gunawardana M; Fanter R; Miller CS; Sanchez D; Yang F; Ellis S; Zhang J; Marzinke MA; Hendrix CW; Kapoor A; Baum MM
    PLoS One; 2017; 12(10):e0185946. PubMed ID: 28982161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Injection Volume and Route of Administration on Dolutegravir In Situ Forming Implant Pharmacokinetics.
    Joiner JB; King JL; Shrivastava R; Howard SA; Cottrell ML; Kashuba ADM; Dayton PA; Benhabbour SR
    Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35335991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting biodegradable implant for sustained delivery of antiretrovirals (ARVs) and hormones.
    Li L; Gatto GJ; Brand RM; Krovi SA; Cottrell ML; Norton C; van der Straten A; Johnson LM
    J Control Release; 2021 Dec; 340():188-199. PubMed ID: 34678316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
    Landovitz RJ; Li S; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; Zhang Y; Tolley E; Sugarman J; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Spreen WR; Cohen MS; McCauley M; Eron JJ
    PLoS Med; 2018 Nov; 15(11):e1002690. PubMed ID: 30408115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next generation 3D-printed intravaginal ring for prevention of HIV and unintended pregnancy.
    Young IC; Srinivasan P; Shrivastava R; Janusziewicz R; Thorson A; Cottrell ML; Sellers RS; Sykes C; Schauer A; Little D; Kelley K; Kashuba ADM; Katz D; Pyles RB; García-Lerma JG; Vincent KL; Smith J; Benhabbour SR
    Biomaterials; 2023 Oct; 301():122260. PubMed ID: 37549505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodegradable polymeric solid implants for ultra-long-acting delivery of single or multiple antiretroviral drugs.
    Maturavongsadit P; Shrivastava R; Sykes C; Cottrell ML; Montgomery SA; Kashuba ADM; Rahima Benhabbour S
    Int J Pharm; 2021 Aug; 605():120844. PubMed ID: 34216767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis.
    Pons-Faudoa FP; Sizovs A; Di Trani N; Paez-Mayorga J; Bruno G; Rhudy J; Manohar M; Gwenden K; Martini C; Chua CYX; Varchi G; Marzinke MA; Grattoni A
    J Control Release; 2019 Jul; 306():89-96. PubMed ID: 31136811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial.
    Hubacher D; Spector H; Monteith C; Chen PL; Hart C
    Am J Obstet Gynecol; 2017 Feb; 216(2):101-109. PubMed ID: 27662799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Securing accelerated access to long-acting injectable cabotegravir for HIV prevention in low- and middle-income countries.
    Jenkins SY; Resar D; Panos Z; Staple A; Watkins M; Ripin D; Amole C
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26101. PubMed ID: 37439082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-delivery of an HIV prophylactic and contraceptive using PGSU as a long-acting multipurpose prevention technology.
    Cohen J; Shull D; Reed S
    Expert Opin Drug Deliv; 2023 Feb; 20(2):285-299. PubMed ID: 36654482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077.
    Blair CS; Li S; Chau G; Cottle L; Richardson P; Marzinke MA; Eshleman SH; Adeyeye A; Rinehart AR; Margolis D; McCauley M; Hendrix CW; Landovitz RJ;
    J Acquir Immune Defic Syndr; 2020 Sep; 85(1):93-97. PubMed ID: 32452972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV.
    Young Holt B; Dellplain L; Creinin MD; Peine KJ; Romano J; Hemmerling A
    Eur J Contracept Reprod Health Care; 2018 Oct; 23(5):326-334. PubMed ID: 30247084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preferred Product Attributes of Potential Multipurpose Prevention Technologies for Unintended Pregnancy and Sexually Transmitted Infections or HIV Among U.S. Women.
    Hynes JS; Sheth AN; Lathrop E; Sales JM; Haddad LB
    J Womens Health (Larchmt); 2019 May; 28(5):665-672. PubMed ID: 30615569
    [No Abstract]   [Full Text] [Related]  

  • 17. Acceptability of a Long-Acting, Multipurpose Vaginal Ring: Findings from a Phase I Trial in the U.S. and Dominican Republic.
    Tolley EE; Zissette S; Taylor J; Hanif H; Ju S; Schwarz J; Thurman A; Tyner D; Brache V; Doncel GF
    J Womens Health (Larchmt); 2022 Sep; 31(9):1343-1352. PubMed ID: 35363574
    [No Abstract]   [Full Text] [Related]  

  • 18. Motivational interviewing to promote long-acting reversible contraception among Rwandan couples wishing to prevent or delay pregnancy.
    Mukamuyango J; Ingabire R; Parker R; Nyombayire J; Easter SR; Wall KM; Tichacek A; Nyirazinyoye L; Kaslow N; Allen S; Karita E
    Am J Obstet Gynecol; 2020 Apr; 222(4S):S919.e1-S919.e12. PubMed ID: 31838122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Jun; 61(24):449-52. PubMed ID: 22717514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective acceptability of a multipurpose technology (MPT) implant in preclinical development to prevent HIV and unplanned pregnancy: Qualitative insights from women end users and health care providers in South Africa and Zimbabwe.
    Nkomo S; Makoni W; Shapley-Quinn MK; Luecke E; Mbatsane E; Manenzhe K; Ahmed K; Johnson LM; Mahaka I; van der Straten A
    PLoS One; 2023; 18(5):e0285711. PubMed ID: 37195918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.